Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 5. Preliminary performance validation of the hydrogel in vivo in a rabbit model of scleral trauma. Preliminary performance validation of the hydrogel.

Published byJoy Underwood Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 5. Preliminary performance validation of the hydrogel in vivo in a rabbit model of scleral trauma. Preliminary performance validation of the hydrogel."— Presentation transcript:

1 Fig. 5. Preliminary performance validation of the hydrogel in vivo in a rabbit model of scleral trauma. Preliminary performance validation of the hydrogel in vivo in a rabbit model of scleral trauma. (A) Design diagrams (a and c) and validation (b) of a custom injection tool to effectively control hydrogel deployment and regulate its temperature. An image of the prototype injector is shown in the bottom right. (B) Two-arm study design to assess safety and efficacy of the hydrogel versus the current standard of care for posterior segment open globe injuries. (C) Images of the surgical procedure in rabbits. A 3-mm, full-thickness linear incision was created in the sclera about 3 mm radial from the limbus, followed by preparation and deployment of the hydrogel through the incision. (D) Representative baseline intraocular pressure (IOP) values showing no statistical difference between eyes of the same animal or any circadian-induced variations; columns show 6.5 ± 0.2, 6.5 ± 0.2, 5.8 ± 0.2, 6.4 ± 0.3, 8.1 ± 0.4, 8.0 ± 0.4, 7.4 ± 0.5, and 8.6 ± 0.4 mmHg (n = 28 per group). (E) Wald test comparison of mean IOP values of the treatment group versus no intervention, after procedure, showed a statistically significant improvement in mean IOP with sealant placed (*P < 0.05 and **P < 0.001). Niki Bayat et al., Sci Transl Med 2017;9:eaan3879 Published by AAAS

Download ppt "Fig. 5. Preliminary performance validation of the hydrogel in vivo in a rabbit model of scleral trauma. Preliminary performance validation of the hydrogel."

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
Fig. 7. Gradient of adipocyte size and FAI around the human coronaries in the presence or absence of coronary atherosclerosis. Gradient of adipocyte size.

Fig. 7. Gradient of adipocyte size and FAI around the human coronaries in the presence or absence of coronary atherosclerosis. Gradient of adipocyte size.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
In vivo function of MeTro sealants using rat incision model of lungs

In vivo function of MeTro sealants using rat incision model of lungs
Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 1. Ketoprofen efficacy in a preclinical model of lymphedema can be attributed to its inhibition of LTB4. Ketoprofen efficacy in a preclinical model.

Fig. 1. Ketoprofen efficacy in a preclinical model of lymphedema can be attributed to its inhibition of LTB4. Ketoprofen efficacy in a preclinical model.
Fig. 4. Ex vivo and in vivo function of the MeTro sealant using rat incision model of arteries. Ex vivo and in vivo function of the MeTro sealant using.

Fig. 4. Ex vivo and in vivo function of the MeTro sealant using rat incision model of arteries. Ex vivo and in vivo function of the MeTro sealant using.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 4. Hydrogel particle size and gelation mechanism.

Fig. 4. Hydrogel particle size and gelation mechanism.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 6. Treatment with a DLK inhibitor is neuroprotective and reverses stress-induced gene expression changes. Treatment with a DLK inhibitor is neuroprotective.

Fig. 6. Treatment with a DLK inhibitor is neuroprotective and reverses stress-induced gene expression changes. Treatment with a DLK inhibitor is neuroprotective.
Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.
Fig. 3. 3RMR response to graded ischemia ex vivo.

Fig. 3. 3RMR response to graded ischemia ex vivo.
Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Similar presentations

Ads by Google